Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have received an average rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.00.
A number of research analysts recently weighed in on ORIC shares. JPMorgan Chase & Co. reduced their target price on ORIC Pharmaceuticals from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, March 27th. HC Wainwright boosted their target price on ORIC Pharmaceuticals from $15.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, March 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Thursday, June 20th. Finally, Citigroup reduced their price target on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th.
Hedge Funds Weigh In On ORIC Pharmaceuticals
ORIC Pharmaceuticals Stock Up 2.3 %
NASDAQ ORIC opened at $7.07 on Wednesday. ORIC Pharmaceuticals has a fifty-two week low of $5.27 and a fifty-two week high of $16.65. The business has a fifty day moving average of $8.45 and a 200-day moving average of $10.24. The stock has a market cap of $476.66 million, a price-to-earnings ratio of -3.93 and a beta of 1.18.
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) last released its earnings results on Monday, May 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.07. As a group, analysts anticipate that ORIC Pharmaceuticals will post -1.68 EPS for the current year.
ORIC Pharmaceuticals Company Profile
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Featured Stories
- Five stocks we like better than ORIC Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.